Timogel® vs Timolol 0.5% Ophthalmic Solution: Efficacy, Safety, and Acceptance
| Autor: | Beatrice Brogliatti, Camilla Alovisi, Mauro Franzone, Federico Grignolo, Teresa Rolle, Daniela Curto |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
medicine.medical_specialty
beta-bloccanti genetic structures efficacia tarapeutica Glaucoma Ocular hypertension Timolol Blood Pressure compliance timololo Tonometry Ocular tollerabilità Heart Rate Surveys and Questionnaires Ophthalmology medicine Humans In patient Prospective Studies Preservative free Antihypertensive Agents Intraocular Pressure business.industry Preservatives Pharmaceutical General Medicine medicine.disease eye diseases glaucoma Treatment Outcome Blood pressure Tolerability Patient Satisfaction Tears Patient Compliance Ocular Hypertension Ophthalmic Solutions Once daily business Gels Glaucoma Open-Angle medicine.drug |
| Zdroj: | European Journal of Ophthalmology. 22:28-33 |
| ISSN: | 1724-6016 1120-6721 |
| DOI: | 10.5301/ejo.5000006 |
| Popis: | Purpose To evaluate the efficacy, safety, and tolerability of Timogel® preservative-free once daily compared to timolol 0.5% ophthalmic solution bid in patients with ocular hypertension (OHT) and patients with primary open-angle glaucoma (POAG). Methods A total of 75 patients with OHT and patients with POAG treated with timolol 0.5% bid with intraocular pressure (IOP) ≤21 mmHg were enrolled. They underwent complete ophthalmologic examination, IOP measurements (at trough and daytime curve), evaluation of side effects, Schirmer test, break-up time [BUT], blood pressure, heart rate, ocular diastolic perfusion pressure measurements, and acceptance (Comparison of Ophthalmic Medications for Tolerability). Patients switched to Timogel® and were re-evaluated 3 months later. The analysis of variance and the Pearson χ2 tests were used to test differences between the treatments. Results Intraocular pressure reduction at trough was 23.6% with timolol 0.5% and 22.3% with Timogel®. No statistical differences were observed in IOP values at trough and in the daytime curve between the 2 treatments. Local and systemic side effects were less frequent with Timogel® (hazard ratio: pConclusions Timogel® preservative-free dosed once every morning has a 24-hour hypotensive effect with a better safety profile than timolol 0.5% bid and it is well-accepted by patients. The once-daily dosing improved acceptance and compliance. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|